Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the pricing of its previously announced underwritten public offering of 5,769,231 shares of its common stock at a public offering price per share of $26.00. The aggregate gross proceeds to Yarrow from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Yarrow, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on September 14, 2026, subject to the satisfaction of customary closing conditions. In addition, Yarrow has granted the underwriters a 30-day option to purchase up to an additional 865,384 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by Yarrow.

Yarrow intends to use the net proceeds from this offering to fund research and development expenses for Yarrow’s pipeline and general corporate purposes, which may include working capital, capital expenditures and other general corporate purposes.

Jefferies, TD Cowen and Guggenheim Securities are acting as joint book-running managers and LifeSci Capital is acting as lead manager for the proposed offering.

A shelf registration statement on Form S-3 relating to these securities was filed with the Securities and Exchange Commission (“SEC”) and was declared effective on August 19, 2026. This offering is being made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov, and, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at [phone], or by email at [e-mail]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [e-mail]; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at [phone], or by email at [e-mail]; or LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, New York 10019, or by email at [e-mail].

Schreibe Deinen Kommentar